An Impeccable Track Record of 37 Years of Scientific Achievements in Health and Longevity
- In 1991, Life Extension sued the United States Food and Drug Administration (FDA) because the FDA failed to approve Tacrine (THA) to treat Alzheimer's disease. While the lawsuit was dismissed on technical grounds, it forced the FDA to finally approve THA seven years after it was shown in a New England Journal of Medicine report to slow the progression of Alzheimer's disease.
- In 1992, Life Extension introduced melatonin to the American public based on overwhelming evidence that this natural hormone is an effective anti-aging therapy. After several books were published extolling melatonin’s multiple benefits, every health food store in the United States began selling it in 1995.
- In 1994, Life Extension warned that the commonly prescribed estrogen and synthetic progestin drugs could increase breast and ovarian cancer risk. Findings published years later confirmed these dangers. The natural hormone-balancing approaches long recommended by Life Extension have been shown to decrease common female cancers.
- In 1996, Life Extension published the first book that integrated hormone replacement, high-dose nutrient supplementation, prescription drugs, and conventional medical treatments for the purpose of preventing and treating 110 diseases that were not being effectively treated by conventional medicine alone.
- In 1996, Life Extension revealed the crucial importance of monitoring blood levels of fibrinogen, a risk factor for cardiovascular disease and stroke. Since then, numerous studies have confirmed that high levels of fibrinogen are indeed a heart attack and stroke risk factor, just like high cholesterol levels.
- In 1996, Life Extension founded the first mail-order blood screening service that offered state-of-the-art tests for age-related diseases directly to the public.
- In 1997, Life Extension published a new theory on why cells malfunction as they age (decline in DNA methylation), and introduced several therapies that could help aging cells to rejuvenate. These therapies, which have been documented by hundreds of studies, are currently being prescribed for the treatment of depression, liver disease and atherosclerosis.
- In 1997, Life Extension recommended that certain patients temporarily take a combination of statin and COX-2 inhibiting drugs to inhibit cancer cell growth. Since then, several studies have confirmed the anti-cancer effects of these drugs that are not commonly associated with cancer therapy.
- In 1997, Life Extension warned about the dangers of taking only the “alpha tocopherol” form of vitamin E. Since then, a number of published studies confirmed that aging people would benefit by also taking the “gamma tocopherol” form of vitamin E that Life Extension has long advocated.
- In 1997, Life Extension introduced a European discovery called s-adenosyl-methionine (SAMe) that safely alleviated depression, arthritis and certain liver disorders. A Harvard study published in 2010 showed that the use of SAMe increased the response rate to conventional anti-depressant drugs by 105%!
- In 1998, Life Extension introduced to the United States a natural herbal supplement (nettle root extract) that has been used for more than ten years in Europe to relieve the symptoms of benign prostatic hypertrophy.
- In 1998, the FDA approved the anti-viral drug ribavirin for use in Hepatitis C patients. Life Extension fought the FDA for 12 years to force them to approve this lifesaving medication.
- In 1998, Life Extension warned how excess estrogen levels in aging men may be a causative factor in the development of prostate cancer and provided easy and safe methods to mitigate these effects.
- In 1998, Life Extension introduced Americans to a Japanese drug called methylcobalamin, a form of vitamin B12 that was particularly effective in protecting the brain against damaging excitotoxicity and also reversing the course of certain neurological disorders.
- In 1999, Life Extension showed how vitamin C may prevent nitroglycerin drug intolerance in patients with coronary artery disease.
- In 1999, Life Extension showed how certain FDA-approved estrogen drugs may not protect against heart disease. A few years later, these very drugs were shown to increase cardiovascular disease in women.